Xueyong Lou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xueyong Lou has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Dongying Nie
2 shared publicationsYanfen Liu
Department of Endocrinology School of Medicine Zhejiang University Jinhua Hospital Jinhua People's Republic of China
2 shared publications- Jun Liu
Department of Internal Medicine, Shaxi People’s Hospital, Taicang, China
1 shared publication Xueyong Lou
Zhejiang University School of Medicine
1 shared publicationYan Fen Liu
Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
1 shared publication- Yanfen Liu
Department of Endocrinology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
1 shared publication
Latest Publications
- Open Access
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47268
Dissecting the causal link between transient hypoglycemic coma and gut-brain axis imbalance – implications for diarrhea pathogenesis: A case report
Rationale: The systemic consequences of hypoglycemic brain injury beyond the central nervous system remain poorly understood. While the brain-gut axis is a pivotal communication network, clinical evidence linking hypoglycemia to gut dysmotility is confounded by comorbidities like autonomic neuropathy. This case report aims to present the first documented evidence of isolated hypoglycemic brain injury inducing transient, profound diarrhea through a hypothesized brain-gut pathway, in a patient with all confounding factors rigorously excluded and premorbid normal gut histology. Patient concerns: A 65-year-old male with type 2 diabetes suffered an insulin overdose, resulting in profound hypoglycemia (glucose 1.8 mmol/L) and a 10-minute comatose state. Twenty-four hours post-hypoglycemia, he developed acute-onset, large-volume watery diarrhea (3–4 episodes daily). Diagnoses: A comprehensive diagnostic workup excluded all common infectious, inflammatory, autoimmune, metabolic, and structural causes. Interventions: The diarrhea proved refractory to a sequential therapeutic regimen including loperamide, smectite, Saccharomyces boulardii, and cholestyramine. Outcomes: The symptoms persisted unabated until their abrupt and complete resolution on day 11, without therapeutic intervention. At 3-month follow-up, the patient remained asymptomatic with normal bowel function and objective tests. Lessons: This case illuminates a novel, self-limiting cerebro-enteral pathway activated by hypoglycemia, which we hypothesize is mediated by blood–brain barrier-disruption and corticotropin-releasing hormone-driven neurohumoral cascades. It underscores the need to consider central nervous system injury in the differential diagnosis of unexplained acute diarrhea and highlights the necessity for monitoring gastrointestinal symptoms post-hypoglycemia.
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47268
Open AccessDissecting the causal link between transient hypoglycemic coma and gut-brain axis imbalance – implications for diarrhea pathogenesis: A case report
Rationale: The systemic consequences of hypoglycemic brain injury beyond the central nervous system remain poorly understood. While the brain-gut axis is a pivotal communication network, clinical evidence linking hypoglycemia to gut dysmotility is confounded by comorbidities like autonomic neuropathy. This case report aims to present the first documented evidence of isolated hypoglycemic brain injury inducing transient, profound diarrhea through a hypothesized brain-gut pathway, in a patient with all confounding factors rigorously excluded and premorbid normal gut histology. Patient concerns: A 65-year-old male with type 2 diabetes suffered an insulin overdose, resulting in profound hypoglycemia (glucose 1.8 mmol/L) and a 10-minute comatose state. Twenty-four hours post-hypoglycemia, he developed acute-onset, large-volume watery diarrhea (3–4 episodes daily). Diagnoses: A comprehensive diagnostic workup excluded all common infectious, inflammatory, autoimmune, metabolic, and structural causes. Interventions: The diarrhea proved refractory to a sequential therapeutic regimen including loperamide, smectite, Saccharomyces boulardii, and cholestyramine. Outcomes: The symptoms persisted unabated until their abrupt and complete resolution on day 11, without therapeutic intervention. At 3-month follow-up, the patient remained asymptomatic with normal bowel function and objective tests. Lessons: This case illuminates a novel, self-limiting cerebro-enteral pathway activated by hypoglycemia, which we hypothesize is mediated by blood–brain barrier-disruption and corticotropin-releasing hormone-driven neurohumoral cascades. It underscores the need to consider central nervous system injury in the differential diagnosis of unexplained acute diarrhea and highlights the necessity for monitoring gastrointestinal symptoms post-hypoglycemia.
- Open Access
- 1 October 2025
- Published by Elmer Press, Inc. in Journal of Endocrinology and Metabolism
- Vol. 15 (4) , 119-129
Mesenchymal Stem Cell in Thyroid Disorders: Hype or Hope?
Thyroid disorders, including hypothyroidism, hyperthyroidism, thyroid cancer, and nodular disease, represent a substantial global health burden. Current therapeutic options are often inadequate, frequently necessitating lifelong hormone replacement or causing irreversible tissue damage. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic platform due to their dual capacity to differentiate into thyroid-like cells and modulate immune dysregulation. This review provides a critical examination of preclinical evidence supporting MSC-based interventions for thyroid disorders. We analyzed studies demonstrating MSC potential in restoring thyroid hormone production via thyrocyte regeneration, rebalancing T-helper 17 (Th17)/regulatory T cell (Treg) cell ratios in autoimmune thyroiditis, and inhibiting tumor progression through paracrine mechanisms. Key challenges, such as tumorigenesis risk from MSC-tumor interactions, source variability, regulatory complexities for standardization, and unresolved issues in differentiation protocols and safety biomarkers, are systematically evaluated. The primary purpose of this review was to assess the therapeutic potential and limitations of MSC-based strategies for treating thyroid disorders. The review emphasizes the critical need for the development of robust translational frameworks that address existing obstacles, including the refinement of differentiation protocols, establishment of safety biomarkers, and exploration of engineered MSC-derived extracellular vesicles with targeted therapies, to bridge the gap between preclinical promise and clinical application.
- 1 October 2025
- Published by Elmer Press, Inc. in Journal of Endocrinology and Metabolism
- Vol. 15 (4) , 119-129
Open AccessMesenchymal Stem Cell in Thyroid Disorders: Hype or Hope?
Thyroid disorders, including hypothyroidism, hyperthyroidism, thyroid cancer, and nodular disease, represent a substantial global health burden. Current therapeutic options are often inadequate, frequently necessitating lifelong hormone replacement or causing irreversible tissue damage. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic platform due to their dual capacity to differentiate into thyroid-like cells and modulate immune dysregulation. This review provides a critical examination of preclinical evidence supporting MSC-based interventions for thyroid disorders. We analyzed studies demonstrating MSC potential in restoring thyroid hormone production via thyrocyte regeneration, rebalancing T-helper 17 (Th17)/regulatory T cell (Treg) cell ratios in autoimmune thyroiditis, and inhibiting tumor progression through paracrine mechanisms. Key challenges, such as tumorigenesis risk from MSC-tumor interactions, source variability, regulatory complexities for standardization, and unresolved issues in differentiation protocols and safety biomarkers, are systematically evaluated. The primary purpose of this review was to assess the therapeutic potential and limitations of MSC-based strategies for treating thyroid disorders. The review emphasizes the critical need for the development of robust translational frameworks that address existing obstacles, including the refinement of differentiation protocols, establishment of safety biomarkers, and exploration of engineered MSC-derived extracellular vesicles with targeted therapies, to bridge the gap between preclinical promise and clinical application.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 3697-3710
The Bidirectional Association Between Metabolic Syndrome and Long-COVID-19
Background: The rapid global spread of a new coronavirus disease known as COVID-19 has led to a significant increase in mortality rates, resulting in an unprecedented worldwide pandemic. Methods: The impact of COVID-19, particularly its long-term effects, has also had a profound effect on the health and well-being of individuals.Metabolic syndrome increases the risk of heart and brain diseases, presenting a significant danger to human well-being. Purpose: The prognosis of long COVID and the progression of metabolic syndrome interact with each other, but there is currently a lack of systematic reports.In this paper, the pathogenesis, related treatment and prognosis of long COVID and metabolic syndrome are systematically reviewed.
- 1 October 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 3697-3710
Open AccessThe Bidirectional Association Between Metabolic Syndrome and Long-COVID-19
Background: The rapid global spread of a new coronavirus disease known as COVID-19 has led to a significant increase in mortality rates, resulting in an unprecedented worldwide pandemic. Methods: The impact of COVID-19, particularly its long-term effects, has also had a profound effect on the health and well-being of individuals.Metabolic syndrome increases the risk of heart and brain diseases, presenting a significant danger to human well-being. Purpose: The prognosis of long COVID and the progression of metabolic syndrome interact with each other, but there is currently a lack of systematic reports.In this paper, the pathogenesis, related treatment and prognosis of long COVID and metabolic syndrome are systematically reviewed.
- 7 August 2024
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 43 (8) , 387-394
The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression
Coronary artery disease (CAD) is associated with a high fatality rate and a heavy global health care burden. Glucagon-like peptide-1 (GLP-1) exerts positive cardiovascular effects, although the molecular mechanisms are unclear. Therefore, this study aimed to verify whether the cardioprotective effects of GLP-1 are mediated through the regulation of micro-RNA (miRNA) expression. Follow-up assessments were conducted for 116 patients with type 2 diabetes mellitus (T2DM) alone (controls) and 123 patients with both T2DM and CAD. After matching, each group comprised 63 patients, and age, body mass index, and serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG), and hemoglobin A1C (HbA1c) were compared. Subsequently, the expression profiles of four circulating miRNAs (miR-203a-3p, miR-429, miR-205-5p, and miR-203b-5p) were assessed via quantitative reverse transcription real-time polymerase chain reaction in the 63 patients with diabetes and CAD between 6 months (baseline) and 12 months after the initiation of GLP-1 receptor (GLP-1R) therapy. As expected, the metabolic factors were significantly improved after 6 months of treatment with GLP-1R compared with pre-treatment values, and the expression levels of two of the miRNAs (miR-203a-3p and miR-429) decreased from baseline levels in those with diabetes and CAD. The results suggest that the cardiovascular benefits induced by GLP-1R are mediated via suppressed expression of two miRNAs: miR-203a-3p and miR-429.
- 7 August 2024
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 43 (8) , 387-394
The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression
Coronary artery disease (CAD) is associated with a high fatality rate and a heavy global health care burden. Glucagon-like peptide-1 (GLP-1) exerts positive cardiovascular effects, although the molecular mechanisms are unclear. Therefore, this study aimed to verify whether the cardioprotective effects of GLP-1 are mediated through the regulation of micro-RNA (miRNA) expression. Follow-up assessments were conducted for 116 patients with type 2 diabetes mellitus (T2DM) alone (controls) and 123 patients with both T2DM and CAD. After matching, each group comprised 63 patients, and age, body mass index, and serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG), and hemoglobin A1C (HbA1c) were compared. Subsequently, the expression profiles of four circulating miRNAs (miR-203a-3p, miR-429, miR-205-5p, and miR-203b-5p) were assessed via quantitative reverse transcription real-time polymerase chain reaction in the 63 patients with diabetes and CAD between 6 months (baseline) and 12 months after the initiation of GLP-1 receptor (GLP-1R) therapy. As expected, the metabolic factors were significantly improved after 6 months of treatment with GLP-1R compared with pre-treatment values, and the expression levels of two of the miRNAs (miR-203a-3p and miR-429) decreased from baseline levels in those with diabetes and CAD. The results suggest that the cardiovascular benefits induced by GLP-1R are mediated via suppressed expression of two miRNAs: miR-203a-3p and miR-429.
- Open Access
- 20 December 2023
- Published by Springer Nature in Research Square
The cardiovascular benefits of glucagon-like peptide-1 receptor agonists as novel diabetes drugs are mediated via the suppression of miR-203a-3p and miR-429 expression
Purpose Coronary artery disease (CAD) is associated with a high fatality rate and a heavy global health care burden. Glucagon-like peptide-1 (GLP-1) exerts positive cardiovascular effects, although the molecular mechanisms are unclear. Therefore, this study aimed to verify whether the cardioprotective effects of GLP-1 are mediated through the regulation of micro-RNA (miRNA) expression. Materials and Methods Follow-up assessments were conducted for 116 patients with type 2 diabetes alone (controls) and 123 patients with both type 2 diabetes and CAD. After matching, each group comprised 63 patients, and age, body mass index, and serum levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and haemoglobin A1C were compared. Subsequently, the expression profiles of four circulating miRNAs (miR-203a-3p, miR-429, miR-205-5p, and miR-203b-5p) were assessed via qRT-PCR in the 63 patients with diabetes and CAD between six months (baseline) and twelve months after the initiation of GLP-1 therapy. Results As expected, the metabolic factors were significantly improved after 6 months of treatment with GLP-1 compared with pre-treatment values, and the expression levels of two of the miRNAs (miR-203a-3p and miR-429) decreased from baseline levels in those with diabetes and CAD. Conclusions The results suggest that the cardiovascular benefits induced by GLP-1 are mediated via suppressed expression of two miRNAs: miR-203a-3p and miR-429.
- 20 December 2023
- Published by Springer Nature in Research Square
Open AccessThe cardiovascular benefits of glucagon-like peptide-1 receptor agonists as novel diabetes drugs are mediated via the suppression of miR-203a-3p and miR-429 expression
Purpose Coronary artery disease (CAD) is associated with a high fatality rate and a heavy global health care burden. Glucagon-like peptide-1 (GLP-1) exerts positive cardiovascular effects, although the molecular mechanisms are unclear. Therefore, this study aimed to verify whether the cardioprotective effects of GLP-1 are mediated through the regulation of micro-RNA (miRNA) expression. Materials and Methods Follow-up assessments were conducted for 116 patients with type 2 diabetes alone (controls) and 123 patients with both type 2 diabetes and CAD. After matching, each group comprised 63 patients, and age, body mass index, and serum levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and haemoglobin A1C were compared. Subsequently, the expression profiles of four circulating miRNAs (miR-203a-3p, miR-429, miR-205-5p, and miR-203b-5p) were assessed via qRT-PCR in the 63 patients with diabetes and CAD between six months (baseline) and twelve months after the initiation of GLP-1 therapy. Results As expected, the metabolic factors were significantly improved after 6 months of treatment with GLP-1 compared with pre-treatment values, and the expression levels of two of the miRNAs (miR-203a-3p and miR-429) decreased from baseline levels in those with diabetes and CAD. Conclusions The results suggest that the cardiovascular benefits induced by GLP-1 are mediated via suppressed expression of two miRNAs: miR-203a-3p and miR-429.